`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`ACRUX DDS PTY LTD. & ACRUX LIMITED
`Petitioners,
`
`v.
`
`KAKEN PHARMACEUTICAL CO., LTD. and
`V ALEANT PHARMACEUTICALS INTERNATIONAL, INC.
`Patent Owner and Licensee.
`
`Case: IPR2017-00190
`U.S. Patent No. 7,214,506
`
`EVIDENTIARY DECLARATION OF MOTONORI MIYAKA WA
`
`Page 1 of3
`
`Page 1 of 4
`
`ACRUX DDS PTY LTD. et al.
`
`EXHIBIT 1664
`
`IPR Petition for
`
`U.S. Patent No. 7,214,506
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`ACRUX DDS PTY LTD. & ACRUX LIMITED
`Petitioners,
`
`v.
`
`KAKEN PHARMACEUTICAL CO., LTD. and
`VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
`Patent Owner and Licensee.
`
`
`
`Case: IPR2017-00190
`U.S. Patent No. 7,214,506
`
`
`
`EVIDENTIARY DECLARATION OF MOTONORI MIYAKAWA
`
`
`
`
`
`
`
`
`
`
`
`
`
`Page 2 of 4
`
`
`
`Page 1 of 3
`
`Kaken Exhibit 2114
`Acrux v. Kaken
`IPR2017-00190
`
`
`
`I, Motonori Miyakawa, hereby declare as follows:
`
`1.
`
`I am employed by Kaken Pharmaceutical Co., Ltd, (“Kaken”). My current
`
`position is Group Manager of Kaken’s Medical Business Development Department,
`
`International Alliance Management Group, and I have been employed by Kaken
`
`since 1996. I have personal knowledge of the matters stated in this declaration,
`
`and if called as a witness I would testify to the same.
`
`2.
`
`I am the custodian of a document that I understand was produced in this
`
`proceeding as Exhibit 2095. Exhibit 2095 is a spreadsheet showing sales data for
`
`the time period between 2014 to 2017. In the course of my work at Kaken, I
`
`generated the spreadsheet from syndicated data obtained in 2016 and 2017 via a
`
`subscription to a database belonging to IMS Health (attached as Exhibit 2110).
`
`That database is commonly relied upon by members of the industry to track
`
`pharmaceutical sales. The data in the spreadsheet accurately reflects the
`
`information obtained from the IMS Health database. I am also familiar with
`
`Kaken’s record keeping practices for the creation and maintenance of this type of
`
`document. It is common practice and was part of my regular duties at Kaken to
`
`obtain and evaluate such data from IMS Health to assess Jublia’s sales numbers.
`
`The sales data obtained from IMS Health are regularly evaluated at Kaken in the
`
`ordinary course of business. Exhibit 2095 was specifically compiled from that
`
`data for this proceeding.
`
`
`
`1
`
`Page 3 of 4
`
`
`
`Page 2 of 3
`
`
`
`3.
`
`I hereby certify that Exhibit 2095 is an accurate and complete duplicate of
`
`the spreadsheet in Kaken’s files.
`
`4.
`
`I hereby further certify that the record duplicated in Exhibit 2095
`
`(A) was made by me at or near the time of occurrence of the matters set
`
`forth in the record and with respect to which I have knowledge,
`
`(B) was made based on information that I obtained from IMS Health,
`
`which provides a commercial service collecting and disseminating
`
`prescription data and has knowledge of those matters; and
`
`(C) was compiled using data from IMS Health typically obtained and kept
`
`by me in the course of regularly conducted business activity for Kaken.
`
`I hereby declare that all statements made herein of my own knowledge are true and
`
`that statements made on information and belief are, to the best of my knowledge,
`
`believed to be true; and further that these statements are made with the knowledge
`
`that willful false statement and the like so made are punishable by fine or
`
`imprisonment, or both, under Section 1001 of Title 18 of the United States Code.
`
`
`
`
`DATE: _________, 2017
`
`
`
`
`
`
`
`
`By:
`
`
`
`
`
`
`Motonori Miyakawa
`
`
`
`
`
`2
`
`Page 4 of 4
`
`
`
`Page 3 of 3
`
`